Immune Responses to Dengue and Zika Viruses—Guidance for T Cell Vaccine Development

Claude Roth, Félix G. Delgado, Etienne Simon-Lorière and Anavaj Sakuntabhai
Additional contact information
Claude Roth: Functional Genetics of Infectious Diseases Unit, Institut Pasteur, 75015 Paris, France
Félix G. Delgado: Functional Genetics of Infectious Diseases Unit, Institut Pasteur, 75015 Paris, France
Etienne Simon-Lorière: Functional Genetics of Infectious Diseases Unit, Institut Pasteur, 75015 Paris, France
Anavaj Sakuntabhai: Functional Genetics of Infectious Diseases Unit, Institut Pasteur, 75015 Paris, France

IJERPH, 2018, vol. 15, issue 2, 1-12

Abstract: Despite numerous efforts to identify the molecular and cellular effectors of the adaptive immunity that induce a long-lasting immunity against dengue or Zika virus infection, the specific mechanisms underlying such protective immunity remain largely unknown. One of the major challenges lies in the high level of dengue virus (DENV) seroprevalence in areas where Zika virus (ZIKV) is circulating. In the context of such a pre-existing DENV immunity that can exacerbate ZIKV infection and disease, and given the lack of appropriate treatment for ZIKV infection, there is an urgent need to develop an efficient vaccine against DENV and ZIKV. Notably, whereas several ZIKV vaccine candidates are currently in clinical trials, all these vaccine candidates have been designed to induce neutralizing antibodies as the primary mechanism of immune protection. Given the difficulty to elicit simultaneously high levels of neutralizing antibodies against the different DENV serotypes, and the potential impact of pre-existing subneutralizing antibodies induced upon DENV infection or vaccination on ZIKV infection and disease, additional or alternative strategies to enhance vaccine efficacy, through T cell immunity, are now being considered. In this review, we summarize recent discoveries about cross-reactive B and T cell responses against DENV and ZIKV and propose guidelines for the development of safe and efficient T cell vaccines targeting both viruses.

Keywords: Zika virus; dengue virus; T cell epitopes; vaccination (search for similar items in EconPapers)
JEL-codes: I I1 I3 Q Q5 (search for similar items in EconPapers)
Date: 2018
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.mdpi.com/1660-4601/15/2/385/pdf (application/pdf)
https://www.mdpi.com/1660-4601/15/2/385/ (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:gam:jijerp:v:15:y:2018:i:2:p:385-:d:132941

Access Statistics for this article

IJERPH is currently edited by Ms. Jenna Liu

More articles in IJERPH from MDPI
Bibliographic data for series maintained by MDPI Indexing Manager ().